Combination of nivolumab (nivo) 1 ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 Study

被引：0

作者：

Lonardi, S. ^{[1
]}

Andre, T. ^{[2
]}

Wong, K. Y. M. ^{[3
]}

Morse, M. ^{[4
]}

McDermott, R. ^{[5
]}

Hill, A. ^{[6
]}

Hendlisz, A. ^{[7
]}

Lenz, H. ^{[8
]}

Leach, J. ^{[9
]}

Moss, R. A. ^{[10
]}

Cao, Z. A. ^{[10
]}

Ledeine, J. ^{[10
]}

Kopetz, S. ^{[11
]}

Overman, M. ^{[11
]}

机构：

[1] Ist Oncol Veneto IRCCS, Padua, Italy

[2] Hop St Antoine, Paris, France

[3] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia

[4] Duke Univ, Off Res Adm, Durham, NC USA

[5] St Vincents Univ Hosp, Dublin, Ireland

[6] Tasman Oncol Res Pty Ltd, Southport, Qld, Australia

[7] Inst Jules Bordet, Brussels, Belgium

[8] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA

[9] Allina Hlth Syst, Minneapolis, MN USA

[10] Bristol Myers Squibb, Princeton, NJ USA

[11] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：3 / 3

页数：1